Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.

[1]  T. Chou,et al.  Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. , 1987, Cancer research.

[2]  J. Bertino,et al.  Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. , 1987, Cancer research.

[3]  J. Bertino,et al.  Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. , 1984, Biochemical pharmacology.

[4]  B. Lathan,et al.  Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. , 1984, Cancer treatment reports.

[5]  J. Mulder,et al.  5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling. , 1981, European journal of cancer & clinical oncology.

[6]  H. Hansen,et al.  The Variability of Individual Tolerance to Methotrexate in Cancer Patients , 1971, British Journal of Cancer.

[7]  D. Dykes,et al.  Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia. , 1987, NCI monographs : a publication of the National Cancer Institute.

[8]  B. Leyland-Jones,et al.  Biochemical modulation: application of laboratory models to the clinic. , 1986, Cancer treatment reports.

[9]  D. W. Fry,et al.  Biochemical pharmacology of the lipophilic antifolate, trimetrexate. , 1984, Advances in enzyme regulation.